Ozempic and GLP-1 Drug Lawsuit (MDL-3094) — Stomach Paralysis Claims

Ozempic lawsuit claims have surged across the country as thousands of patients report severe gastrointestinal injuries. These lawsuits allege that manufacturers of GLP-1 receptor agonist drugs failed to warn about risks of stomach paralysis. The litigation has been consolidated into a federal multidistrict litigation in Pennsylvania. As of May 2026, approximately 3,636 cases are pending in MDL-3094. If you used Ozempic, Wegovy, Mounjaro, or similar drugs and suffered serious digestive injuries, you may qualify to file a claim.

Case Timeline

Last checked: May 16, 2026

Advertisement

  • April 30, 2026: Eli Lilly’s GLP-1 lawsuit against Houston’s Empower Pharmacy partially dismissed – Houston Chronicle (Houston Chronicle)
  • May 15, 2026: Judge dismisses part of Eli Lilly’s GLP-1 lawsuit against Houston’s Empower Pharmacy – MSN (MSN)
  • May 11, 2026: DOJ sues OhioHealth over alleged anticompetitive hospital contracts; Novo to slash Ozempic, Wegovy prices up to 50% in 2027; lightweight ‘exoskeleton’ helps stroke survivors walk – Morning Medical Update – Medical Economics (Medical Economics)
  • May 15, 2026 (Case Status): MDL-3094 case count has grown to 3,636 pending actions as of May 1, 2026; a separate NAION/vision-loss MDL (No. 3163) now has 86 cases. (Court Record)
  • May 15, 2026 (Other): Presiding judge is now Karen S. Marston (E.D. Pa.), not Gene E.K. Pratter — verify whether reassignment occurred. (Court Record)
  • May 15, 2026 (Bellwether Date): No bellwether trials have been scheduled yet; bellwether case selection is expected later in 2026, with trials likely extending into 2027. (Court Record)
  • May 15, 2026 (Ruling): Judge Marston scheduled a Science Day for June 2, 2026 in the NAION/vision-loss MDL (MDL-3163), giving each side 2.5 hours to present non-adversarial scientific evidence. (Court Record)
  • May 15, 2026 (Settlement): No global settlement has been announced in either MDL; legal analysts project mass settlements are unlikely before late 2027, with projected individual values of $100K–$2M+ depending on injury severity. (Court Record)
  • May 15, 2026 (Other): FDA warning activity continues around GLP-1 drugs; 75% of MDL-3094 complaints cite gastroparesis, 18% cite ileus, 8% cite gallbladder complications. (Court Record)
  • What Is the Ozempic Lawsuit About?

    The Ozempic lawsuit centers on GLP-1 receptor agonist medications prescribed for type 2 diabetes and weight loss. These drugs include semaglutide products like Ozempic, Wegovy, and Rybelsus made by Novo Nordisk. They also include tirzepatide products like Mounjaro and Zepbound made by Eli Lilly. Plaintiffs allege the manufacturers knew about serious gastrointestinal risks but failed to adequately warn patients and doctors.

    The primary injury alleged is gastroparesis, also called stomach paralysis. This condition causes the stomach to empty food abnormally slowly. Roughly 75 percent of cases in the MDL involve gastroparesis claims. Other injuries include ileus, which is intestinal blockage, accounting for about 18 percent of claims. Gallbladder injuries make up approximately 8 percent. Many plaintiffs report chronic nausea, vomiting, and severe abdominal pain lasting months or years.

    In September 2023, the FDA updated the Ozempic label to include a warning about ileus. Then in January 2025, the label was revised again. It now states that Ozempic is “not recommended in patients with severe gastroparesis.” However, plaintiffs argue these warnings came too late. They contend the manufacturers had earlier evidence of these risks and chose not to disclose them promptly.

    MDL Case Status and Key Facts

    Detail Information
    MDL Number 3094
    Full Title In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
    Presiding Judge Hon. Karen Spencer Marston
    Federal District Eastern District of Pennsylvania
    Approximate Case Count 3,636 (as of May 2026)
    Consolidated September 2023
    Key Defendants Novo Nordisk, Eli Lilly
    Bellwether Trials Expected late 2026 or early 2027

    The Judicial Panel on Multidistrict Litigation consolidated these cases in September 2023. Judge Marston oversees all pretrial proceedings in Philadelphia. Fact discovery closed in late 2025. Expert reports from both sides were filed in early 2026. As a result, the litigation is now entering the critical Daubert motion phase.

    On August 15, 2025, Judge Marston issued a significant causation ruling. The order requires any plaintiff claiming gastroparesis to show a diagnosis based on a properly performed gastric emptying study. This raised the evidentiary bar considerably. Bellwether trial selection is expected by mid-2026. A separate MDL, number 3163, handles vision loss claims related to these same drugs.

    Who Qualifies for the Ozempic Lawsuit?

    You might be eligible for the Ozempic lawsuit if you meet several criteria. First, you must have taken a GLP-1 receptor agonist medication. This includes Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, or Trulicity. Second, you must have developed a qualifying injury after starting the medication. Typically, the most common qualifying conditions are gastroparesis, ileus, and gallbladder disease.

    Medical documentation is essential for any Ozempic lawsuit claim. For example, gastroparesis claims require a confirmed diagnosis through a gastric emptying scintigraphy study. You will also need records showing when you started and stopped the medication. Hospital records, emergency room visits, and surgical reports strengthen your case. In most cases, a clear timeline connecting drug use to injury onset is critical.

    There is no single cutoff date for when the drug was used. However, the strength of your claim depends on several factors. These include the severity of your injury, duration of drug use, and your medical history. A licensed attorney can evaluate whether your specific situation qualifies. Many firms handling Ozempic lawsuit cases offer free initial consultations.

    How to File an Ozempic Lawsuit Claim

    The first step in filing an Ozempic lawsuit is consulting a qualified mass tort attorney. Look for firms with experience in pharmaceutical litigation. Many attorneys work on a contingency basis. This means you pay nothing upfront. They only collect fees if you receive compensation. An attorney can review your medical records and determine claim viability.

    After retaining counsel, your attorney will file a complaint. If filed in federal court, your case will typically be transferred to MDL-3094 in Pennsylvania. You will need to complete a Plaintiff Fact Sheet. This detailed questionnaire covers your medical history, drug usage, and injuries. Accurate and thorough responses are important. Additionally, your attorney may need to obtain your pharmacy records and medical imaging results.

    Statute of limitations deadlines vary by state. In most cases, you have two to three years from when you discovered the injury. Some states apply a “discovery rule.” This means the clock starts when you became aware of the connection between the drug and your condition. However, waiting too long can jeopardize your claim. Consulting an attorney promptly is strongly recommended.

    Settlement Updates and What to Expect

    As of May 2026, no global settlement has been reached in the Ozempic lawsuit. The litigation remains in pretrial stages. Bellwether trials have not yet occurred. These initial trial cases are typically selected to test the strength of both sides’ arguments. Their outcomes heavily influence future settlement negotiations. Legal analysts project a resolution window of 2026 through 2029.

    📨 Get Free Mass Tort Guides Alerts

    Free · No spam · Unsubscribe anytime

    Settlement amounts in pharmaceutical MDLs vary widely based on injury severity. Factors that affect potential compensation include the type of injury, duration of suffering, and medical costs incurred. Surgical interventions like gallbladder removal may increase claim value. However, no specific payout amounts are guaranteed. Each Ozempic lawsuit claim is evaluated individually based on its facts.

    The August 2025 causation ruling could significantly affect outcomes. Cases with strong diagnostic evidence may fare better. Conversely, claims lacking proper gastric emptying studies may face challenges. The Daubert hearing results, expected in mid-2026, will determine which expert testimony is admissible at trial. These rulings will shape the trajectory of the entire Ozempic lawsuit litigation.

    State-by-State Considerations

    While most Ozempic lawsuit cases are consolidated in the federal MDL, state laws still matter. Each plaintiff’s claim is governed by their home state’s tort laws. For example, states like Texas and Florida have enacted tort reform measures that may cap damages. Meanwhile, states such as Pennsylvania, New Jersey, and California tend to be more plaintiff-friendly. New Jersey also hosts parallel multicounty litigation alongside the federal MDL.

    Statute of limitations periods differ by state and can range from one to six years. Some states have stricter rules about expert testimony requirements. Others have different standards for proving causation. As a result, where you live can meaningfully affect your case. You can learn more about how your state’s laws apply on our state-by-state tort reform guide. Consulting a licensed attorney familiar with your state’s rules is essential.

    Frequently Asked Questions

    Is the Ozempic lawsuit still accepting new cases?

    Yes, new Ozempic lawsuit cases continue to be filed and added to MDL-3094. No filing deadline has been set by the court for joining the MDL. However, your individual statute of limitations still applies. Contact a mass tort attorney as soon as possible to protect your rights.

    Can I still take Ozempic if I file a lawsuit?

    Filing an Ozempic lawsuit does not require you to stop taking the medication. That is a medical decision between you and your doctor. However, your continued use of the drug may be relevant to your case. Your attorney can advise you on how this might affect your claim.

    How long will the Ozempic lawsuit take to resolve?

    Pharmaceutical MDL cases typically take three to six years from consolidation to resolution. MDL-3094 was consolidated in September 2023. Bellwether trials are expected to begin in late 2026 or early 2027. Settlement negotiations often follow bellwether outcomes. In most cases, plaintiffs should expect a timeline extending into 2027 or beyond.

    Check If You May Qualify

    Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.

    Official Sources & Resources

    For verified mass tort and MDL information:

    • JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
    • DOJ: justice.gov — settlement announcements and press releases
    • FDA: fda.gov — drug recalls, warning letters, and safety alerts
    • CDC: cdc.gov — health condition data and exposure guidelines
    • EPA: epa.gov — environmental contamination data
    • Cornell LII: law.cornell.edu — plain-English legal definitions

    Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.

    Related Guides

    Going through divorce too? Compare state laws at Divorce Help Guide. Affected by a recalled drug as a Medicare patient? See Medicare Cover Guide. Just diagnosed with a serious illness? Compare life insurance at Life Insure Guide. PFAS in your water? Check homeowners coverage at Home Insure Guide.